Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01682031 · ClinicalTrials.gov registry record · Phase 2
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01682031 is a Phase 2 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 18 participants.
The verdict
NCT01682031, a Phase 2 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy. SLM may help prevent or reduce mucositis, or mouth sores, in patients receiving chemotherapy and radiation therapy. It is not yet known whether SLM is more effective than a placebo in reducing mucositis
Interventions
- OTHER placebo
- DRUG cisplatin
- PROCEDURE quality-of-life assessment
- RADIATION radiation therapy
- DIETARY_SUPPLEMENT selenomethionine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01682031
The ClinicalTrials.gov registry entry for NCT01682031 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01682031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01682031 about?
NCT01682031 is a clinical study titled "Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy". This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy. SLM may help prevent or reduce mucositis, or mouth sores, in patients receiving chemotherap...
What is the current status of trial NCT01682031?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2009-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01682031?
The interventions under investigation include: placebo (OTHER), cisplatin (DRUG), quality-of-life assessment (PROCEDURE), radiation therapy (RADIATION), selenomethionine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01682031?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.